Last updated: April 23, 2026
Who supplies dextroamphetamine APIs and finished dosage in major markets?
Dextroamphetamine is a controlled psychostimulant. Supply is concentrated in a limited set of API and finished-dose manufacturers that can operate under tight regulatory, quota, and diversion-control frameworks. The suppliers below are those that are publicly documented in regulatory filings, product monographs, and established distribution channels tied to dextroamphetamine products.
What are the core supplier categories?
- API manufacturers (dextroamphetamine base or dextroamphetamine sulfate)
- Produce the active pharmaceutical ingredient for internal formulation or for sale to formulators under controlled chemical and regulatory requirements.
- Finished-dose manufacturers
- Produce tablets/capsules and package under GMP and controlled-substance registrations.
- Authorized distributors
- Distribute finished dosage forms under controlled-substance licensing (varies by country and schedule status).
Which companies supply dextroamphetamine finished dosage in the U.S.?
The U.S. market includes multiple branded and authorized generics for dextroamphetamine sulfate. Suppliers in the chain typically include:
- Teva Pharmaceuticals (generic and/or authorized supply relationships for dextroamphetamine sulfate tablets in the U.S. ecosystem)
- Mylan/Viatris (generic ecosystem)
- Amneal Pharmaceuticals (generic ecosystem)
- Par Pharmaceuticals (generic ecosystem)
- Sandoz (generic ecosystem)
Which companies are known dextroamphetamine API suppliers?
Publicly observable API supplier identity is more fragmented than finished-dose identification because API sales often occur under confidential agreements and through intermediaries. Where API attribution is explicitly tied to finished-dose submissions and monographs, the API supply base often includes:
- Xiangyu Pharmaceuticals and other China-based controlled-chemical API firms that support CNS stimulant intermediates and API production pipelines (based on recurring presence in global stimulant API landscapes)
- European and Indian API producers that supply psychostimulant salts to generics in regulated channels (based on their documented role in CNS API supply contracts)
How to map supply for specific strengths and dosage forms
Dextroamphetamine is marketed mainly as:
- Dextroamphetamine sulfate tablets
- Dextroamphetamine sulfate extended-release capsules (where applicable by market)
- Dextroamphetamine sulfate tablets (immediate release)
Supply risk and supplier switching depend on:
- Strength (for example, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg in typical product lineups in various markets)
- Release profile (immediate vs extended release)
- Container/label configuration (bottles, blisters; language/labeling requirements)
What are the regulatory constraints that shape supplier availability?
Dextroamphetamine supply is constrained by:
- Controlled substance registration and quota in each jurisdiction
- Diversion-control obligations across manufacturing, distribution, and wholesaling
- GMP documentation and site-specific regulatory inspection readiness
- Import/export controls on controlled chemical precursors and finished controlled substances
- Schedule classification (which drives permitting for manufacturing and distribution)
What supplier documentation is typically used to validate sources?
For due diligence, supply teams normally validate through:
- Regulatory product listings (drug product and applicant/manufacturer identity)
- NDC-linked product labeling to identify manufacturer and distributor
- Drug master files (DMFs) and API reference listings when accessible
- Inspection outcomes and GMP status for sites producing controlled CNS APIs
Where does supply information show up most reliably?
- Finished-dose NDC labels and packaging (highest reliability for identifying who actually releases product)
- National drug approval databases (e.g., FDA’s drug product and label records)
- Pharmacopoeia monographs (for substance specifications and salt forms, not always for supplier identity)
- Controlled-substance licensing records (country-specific availability and usability)
Practical supplier short-listing approach for procurement
Procurement teams typically:
- Identify the exact salt and dosage form (dextroamphetamine sulfate vs other forms, IR vs ER).
- Pull the NDC/approval identifier tied to each strength.
- Select suppliers based on the labeled manufacturer for the product and the licensed distributor for sourcing continuity.
- Run a site-level check against inspection and controlled-substance compliance history.
Key Takeaways
- Dextroamphetamine supply is concentrated among a small number of qualified suppliers because it is controlled and diversion-sensitive.
- Finished-dose supplier identity is usually clearer than API identity because product labels and regulatory product listings expose the manufacturer and NDC-linked release chain.
- Procurement should validate supply strictly at the salt, dosage form, strength, and labeled manufacturer level, then confirm controlled-substance compliance and GMP status for continuity.
FAQs
1) Are there many API suppliers for dextroamphetamine?
The API supplier base is limited relative to non-controlled CNS drugs, and API sourcing is often mediated through contracts and intermediaries under controlled-substance compliance requirements.
2) Is dextroamphetamine supplied as base or sulfate?
In most regulated markets, it is supplied primarily as dextroamphetamine sulfate, because commercial products commonly use that salt for dosing consistency.
3) Can a finished-dose generic be sourced from multiple manufacturers?
Yes, but the correct approach is to validate by strength and NDC, since the same active ingredient can be manufactured and released by different labeled manufacturers across distribution lots.
4) Why does dextroamphetamine availability fluctuate?
Availability is driven by controlled-substance quotas, manufacturing slot availability, GMP and inspection readiness, and import/export constraints on controlled chemicals and finished dosage forms.
5) What is the best way to confirm the real supplier for procurement?
Use the labeled manufacturer and NDC/product records for the exact strength and dosage form, then confirm licensing and GMP status for the supply chain.
References
[1] U.S. Food and Drug Administration. Drug Approval Tables and Product Labeling (for approved dextroamphetamine sulfate products).
[2] U.S. Drug Enforcement Administration. Controlled Substances schedules and regulatory framework (for diversion-control context).
[3] U.S. National Library of Medicine. NDC and drug product record-linked information (for manufacturer identification via product listings).
[4] European Medicines Agency. Public assessment and product information resources for controlled CNS medicines (site-level compliance context).
